about
Hsp90 Inhibitors for the Treatment of Chronic Myeloid LeukemiaHuman T-Cell Lymphotropic Virus Types 1 and 2 Seropositivity among Blood Donors at Mbarara Regional Blood Bank, South Western Uganda.Postinduction Supportive Care of Pediatric Acute Myelocytic Leukemia: Should Patients be Kept in the Hospital?Characteristics of Adult T-Cell Leukemia/Lymphoma Patients with Long Survival: Prognostic Significance of Skin Lesions and Possible Beneficial Role of Valproic Acid.Isochromosome 17q in Chronic Lymphocytic Leukemia.Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision AnalysisImportant genes in the pathogenesis of 5q- syndrome and their connection with ribosomal stress and the innate immune system pathway.Cotranscriptional Chromatin Remodeling by Small RNA Species: An HTLV-1 PerspectiveMycophenolic Acid overcomes imatinib and nilotinib resistance of chronic myeloid leukemia cells by apoptosis or a senescent-like cell cycle arrest.Clinical experience using vitamin d and analogs in the treatment of myelodysplasia and acute myeloid leukemia: a review of the literature.Diffuse large B-cell lymphoma in human T-lymphotropic virus type 1 carriers.Myeloid sarcoma: clinicopathologic, cytogenetic, and outcome analysis of 21 adult patients.Influence of Methylenetetrahydrofolate Reductase C677T, A1298C, and G80A Polymorphisms on the Survival of Pediatric Patients with Acute Lymphoblastic Leukemia.Immunopathogenesis of human T-cell leukemia virus type-1-associated myelopathy/tropical spastic paraparesis: recent perspectivesPKCδ Regulates Translation Initiation through PKR and eIF2α in Response to Retinoic Acid in Acute Myeloid Leukemia CellsClinical Trials and Treatment of ATL.MicroRNAs in Acute Myeloid Leukemia and Other Blood Disorders.Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive TherapyPhysical Activity in Adolescents following Treatment for Cancer: Influencing Factors.Polymorphisms of MTHFR Associated with Higher Relapse/Death Ratio and Delayed Weekly MTX Administration in Pediatric Lymphoid Malignancies.Molecularly targeted therapies in multiple myelomaImpact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia.In Vitro Characterization of Valproic Acid, ATRA, and Cytarabine Used for Disease-Stabilization in Human Acute Myeloid Leukemia: Antiproliferative Effects of Drugs on Endothelial and Osteoblastic Cells and Altered Release of Angioregulatory MediatorComparison of the Genetic Organization, Expression Strategies and Oncogenic Potential of HTLV-1 and HTLV-2.Pathogenesis of Metastatic Calcification and Acute Pancreatitis in Adult T-Cell Leukemia under Hypercalcemic State.Wnt/ß-catenin: a new therapeutic approach to acute myeloid leukemia.Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation.New Quantitative Method to Identify NPM1 Mutations in Acute Myeloid Leukaemia.Characterization of Kaposi's Sarcoma-Associated Herpesvirus-Related Lymphomas by DNA Microarray Analysis.Is There a Role for HTLV-1-Specific CTL in Adult T-Cell Leukemia/Lymphoma?Clinical trials of adult T-cell leukaemia/lymphoma treatment.Retinoid differentiation therapy for common types of acute myeloid leukemia.Influence of IL10 (G1082A) and TNFα (G308A) Polymorphisms on the Survival of Pediatric Patients with ALLMolecular and Cellular Mechanism of Leukemogenesis of ATL: Emergent Evidence of a Significant Role for HBZ in HTLV-1-Induced Pathogenesis.Differentiation and cell survival of myeloid leukemia cells.Understanding and Targeting the Wnt/β-Catenin Signaling Pathway in Chronic Leukemia.HTLV-1 Infection and Its Associated Diseases.Myeloid Sarcoma: The Clinician's Point of ViewCytotoxicity of algae extracts on normal and malignant cells.Rapid infusion rituximab for maintenance therapy: is it feasible?
P1433
Q26771790-B059C421-D8B5-4A99-A435-2E7B4846F8F3Q33458088-303ED90F-1F07-4340-A75D-CA65D990A395Q34346926-7CB11C95-C05E-445E-ABB9-06BA05B40EB2Q35833900-5C88DEFB-C0DE-45FF-89B0-90B16327AC8AQ36366951-059B1DBF-ECC4-499C-9340-AEB796CF23DFQ36400944-3BCA6ADB-262C-4754-8F54-EE0B72688954Q36417421-B8B6A9DC-7DB5-4EA1-8311-1F19CB0F2AC4Q36417492-6E7FDB6F-D016-47CD-A296-E6F7D0DEEA76Q36417539-B355C85A-8D3D-4F30-A7D4-176CF0CE4C9CQ36417543-59750AA7-8C5E-4D77-9D5B-4F17DA22E865Q36422084-B8C40A40-0045-4002-8DC7-15D197F8ECE9Q36422092-8A8CEE4D-C3DA-45EF-BCF9-AA0B0E5217F4Q36422106-ACE59997-E8BB-40DD-AF5D-187B40FBB5D6Q36422111-22FC46F8-229F-42A8-BEEB-A63EDADD1878Q36422120-3C4C59F4-5400-4378-A43E-BFAFB587D1C4Q36422133-9B217EB6-4F04-47CF-9229-B36F28E03E02Q36422143-8AC29420-735E-4123-B45C-66A603A0C747Q36848774-8E5C28C3-670D-4FB8-8F04-43EF0C943EE9Q37217985-0F11BE24-881B-48D9-BFD2-FC52E92C614DQ37413286-F9AFBE12-10D9-4CF8-8315-4884BB7CC14CQ38211866-5CC35AA2-8753-4B6F-9CB6-964EDDEC07F0Q38681322-F8EA8844-3029-4ADB-8211-65079F47A6C5Q39023971-D015CF98-89EA-40F5-8F75-5FFDFEC74DD5Q39392791-7AAE7DDA-5BB0-4998-9DBA-67C9464043A4Q39445928-16449DAA-9882-47B4-B26A-98EF5DBA38C5Q39799555-9A67A9F2-02E5-4280-8897-27702AEE53E1Q40140538-83C21EA1-D7B7-4779-BC6B-2137834C9313Q40567402-A67EC108-F31D-4986-9C74-2A03482DBA69Q41722814-0C4DEA0F-DAEF-42D6-BA40-D3566C7A8FE6Q41723007-90C91DF4-539A-4F43-AF2F-861B8CB5DF48Q41723608-228E4BB6-1F5B-456A-BD9F-05BE4ACA3F70Q41723841-8E30EA76-B23E-43F4-96C5-BEDD89185885Q41723896-B49A86BA-9EB6-46A4-9232-0AA3363102E1Q41724491-4EBB3A1B-8D2D-4CC6-BBBD-9834E64BC23DQ41724912-0B84B8D9-37DC-4D6F-BCCD-CA0509DD251EQ41725453-EF7F69F5-7B17-40C8-945F-C84EFBCC846EQ41727115-9714A5E4-B457-4E02-A3B1-58F3520C3A67Q41727209-8B70ACF4-67C2-4F8D-8AA4-672B7CB9D1FBQ41772109-CE9C81D8-8591-49C5-B62E-FD33E1341807Q41826129-2E55B6A1-A58A-4EA4-810D-7DE9163970B9
P1433
description
journal
@en
revista científica
@es
rivista scientifica
@it
wetenschappelijk tijdschrift van Hindawi Publishing Corporation
@nl
wissenschaftliche Fachzeitschrift
@de
name
Leukemia Research and Treatment
@ast
Leukemia Research and Treatment
@en
Leukemia Research and Treatment
@es
Leukemia Research and Treatment
@it
Leukemia Research and Treatment
@nl
type
label
Leukemia Research and Treatment
@ast
Leukemia Research and Treatment
@en
Leukemia Research and Treatment
@es
Leukemia Research and Treatment
@it
Leukemia Research and Treatment
@nl
prefLabel
Leukemia Research and Treatment
@ast
Leukemia Research and Treatment
@en
Leukemia Research and Treatment
@es
Leukemia Research and Treatment
@it
Leukemia Research and Treatment
@nl
P3181
P1055
P1156
21100853512